Latham & Watkins Advises Affini-T Therapeutics, Inc. in Its US$175 Million Financing

Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has announced the completion of an oversubscribed US$175 million financing co-led by Vida Ventures and Leaps by Bayer, the impact investment unit of Bayer. Additional investors participating in the round include Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, Fred Hutchinson Cancer Research Center, and other leading blue chip life science investors. With proceeds from this financing, the company will operationalize its platform discovery engine and seek to drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. To enable and accelerate growth, the company has established a bi-coastal US presence with research labs in Seattle, Washington and headquarters and manufacturing infrastructure in Boston, Massachusetts.

Latham & Watkins LLP represents Affini-T Therapeutics, Inc. in the transaction with a corporate deal team led by Boston partner Stephen Ranere and New York partner Nathan Ajiashvili, with Boston associates Luke Schafer and Galina Vujovic.